Animal study vs human trial explained

The research ladder

Medical evidence is built in steps. Each step answers a harder question.

1. Lab studies (in vitro). Cells or tissue in a dish. These show whether something can happen at all.
2. Animal studies (in vivo). Usually mice or rats. These test effects and safety in a whole living body, but not a human one.
3. Human clinical trials. Before testing an unapproved drug in people, the sponsor files an Investigational New Drug application with FDA.^[1] Trials then move through phases.^[2]
4. Approval and follow up. FDA reviews the evidence. After approval, safety tracking continues in what is called Phase 4.^[3]

Phases of clinical trials

Phase	Who and how many	Main question	Share that move on
Phase 1	About 20 to 100 healthy volunteers or people with the condition	Is it safe, and what dose range is tolerated?	About 70 percent
Phase 2	Up to several hundred people with the condition	Does it work, and what are the side effects?	About 33 percent
Phase 3	About 300 to 3,000 people with the condition	Does it work in a larger group, and what rarer side effects show up?	About 25 to 30 percent
Phase 4	Several thousand people, after approval	How safe and useful is it in everyday use?	Not applicable

Figures are from FDA.^[2] NIH describes similar group sizes.^[4]

Why animal results often fail in people

A large 2024 review looked at 367 treatments tested in animals for 54 human diseases. About half reached any human study, 40 percent reached a randomized trial, and only 5 percent were ever approved. On average it took 5 years to reach human study and 10 years to reach approval.^[5]

An older study followed 76 of the most cited animal studies from top journals. Only 37 percent were later confirmed in human randomized trials. Another 18 percent were contradicted, and the rest were never tested in people.^[6]

The 2024 review points to several reasons:^[5]

• Many animal studies skip basic safeguards such as random assignment and blinding, so their results can be too rosy.
• Lab animals are often young and healthy, while patients are often older and have other conditions.
• Effects tend to shrink as a treatment moves from animals to early trials to large trials.
• Early human trials are often too small to give a clear answer.

What "randomized," "placebo" and "double blind" mean

• Randomized means people are put into groups by chance, not by choice. This keeps the groups alike, so differences in results come from the treatment.^[3]
• Placebo means a look alike product with no active ingredient. A placebo group shows how much change happens from time, expectation or normal ups and downs.^[3]
• Double blind means neither the volunteers nor the research team know who got the real treatment. This reduces bias.^[3]

A study that is randomized, placebo controlled and double blind is the strongest single kind of test. A study with none of these can still be useful, but it cannot prove a treatment works.

How to tell study types apart in a headline

If the headline or post says	It probably means
"In mice," "in rats," "animal model"	An animal study. No proof it works in people.
"In cells," "test tube," "in vitro," "lab study"	A lab study. Even further from people.
"Case report," "patients reported," a personal story	One or a few people, no comparison group.
"Pilot," "open label," "small study"	Early human data, usually without a placebo group.
"Randomized, placebo controlled," "Phase 3"	Strong human evidence, if the study is large and published.
"Review," "meta analysis"	A summary of other studies. Only as good as the studies inside it.

To check a claim, find the actual paper on PubMed and read the abstract. Look for the species, how many people took part, whether there was a comparison group, and whether the trial was registered on ClinicalTrials.gov.

Why this matters for peptides

Many peptides popular online rest mostly on animal data. When FDA reviewed BPC-157 for an advisory meeting in 2026, it found only five clinical studies, using routes such as enemas and infusions, and no human data on how the body handles it for routes people commonly use.^[7] FDA lists TB-500 as having no human exposure data.^[8] Strong results in rats are a reason to run human trials, not a substitute for them.

Sources

1. U.S. Food and Drug Administration. Investigational New Drug (IND) Application. FDA page
2. U.S. Food and Drug Administration. The Drug Development Process, Step 3: Clinical Research. FDA page
3. National Institutes of Health. NIH Clinical Research Trials and You: Glossary of Common Terms. NIH page
4. National Institutes of Health. NIH Clinical Research Trials and You: The Basics. NIH page
5. Ineichen BV, Furrer E, Grüninger SL, Zürrer WE, Macleod MR. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLoS Biol. 2024;22(6):e3002667. PMID 38870090
6. Hackam DG, Redelmeier DA. Translation of Research Evidence From Animals to Humans. JAMA. 2006;296(14):1731. doi:10.1001/jama.296.14.1731
7. U.S. Food and Drug Administration. FDA Evaluation of BPC-157 Related Bulk Drug Substances. Briefing document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. FDA briefing document (PDF)
8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. FDA list